AcelRx Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.69
- Today's High:
- $0.7299
- Open Price:
- $0.725
- 52W Low:
- $1.15
- 52W High:
- $8.924
- Prev. Close:
- $0.72
- Volume:
- 357190
Company Statistics
- Market Cap.:
- $10.66 million
- Book Value:
- 3.676
- Revenue TTM:
- $1.52 million
- Operating Margin TTM:
- -2102.17%
- Gross Profit TTM:
- $-5030000
- Profit Margin:
- 3111.24%
- Return on Assets TTM:
- -33.15%
- Return on Equity TTM:
- 0%
Company Profile
AcelRx Pharmaceuticals Inc had its IPO on 2011-02-14 under the ticker symbol ACRX.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. AcelRx Pharmaceuticals Inc has a staff strength of 20 employees.
Stock update
Shares of AcelRx Pharmaceuticals Inc opened at $0.73 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $0.69 - $0.73, and closed at $0.7.
This is a -2.78% slip from the previous day's closing price.
A total volume of 357,190 shares were traded at the close of the day’s session.
In the last one week, shares of AcelRx Pharmaceuticals Inc have slipped by -2.78%.
AcelRx Pharmaceuticals Inc's Key Ratios
AcelRx Pharmaceuticals Inc has a market cap of $10.66 million, indicating a price to book ratio of 0.6895 and a price to sales ratio of 11.8034.
In the last 12-months AcelRx Pharmaceuticals Inc’s revenue was $1.52 million with a gross profit of $-5030000 and an EBITDA of $-30208000. The EBITDA ratio measures AcelRx Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, AcelRx Pharmaceuticals Inc’s operating margin was -2102.17% while its return on assets stood at -33.15% with a return of equity of 0%.
In Q3, AcelRx Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 72.8%.
AcelRx Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 1.0597
- Trailing PE
- 0.2142
- PEG
- 0
Its diluted EPS in the last 12-months stands at $6.07 per share while it has a forward price to earnings multiple of 1.0597 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AcelRx Pharmaceuticals Inc’s profitability.
AcelRx Pharmaceuticals Inc stock is trading at a EV to sales ratio of 10.2797 and a EV to EBITDA ratio of 0.3094. Its price to sales ratio in the trailing 12-months stood at 11.8034.
AcelRx Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $48.31 million
- Total Liabilities
- $15.65 million
- Operating Cash Flow
- $4.44 million
- Capital Expenditure
- $158000
- Dividend Payout Ratio
- 0%
AcelRx Pharmaceuticals Inc ended 2023 with $48.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $48.31 million while shareholder equity stood at $27.54 million.
AcelRx Pharmaceuticals Inc ended 2023 with $8.82 million in deferred long-term liabilities, $15.65 million in other current liabilities, 7000.00 in common stock, $-418345000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $12.73 million and cash and short-term investments were $15.93 million. The company’s total short-term debt was $9,246,000 while long-term debt stood at $0.
AcelRx Pharmaceuticals Inc’s total current assets stands at $24.54 million while long-term investments were $0 and short-term investments were $3.19 million. Its net receivables were $512000.00 compared to accounts payable of $2.00 million and inventory worth $874000.00.
In 2023, AcelRx Pharmaceuticals Inc's operating cash flow was $4.44 million while its capital expenditure stood at $158000.
Comparatively, AcelRx Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $0.7
- 52-Week High
- $8.924
- 52-Week Low
- $1.15
- Analyst Target Price
- $80
AcelRx Pharmaceuticals Inc stock is currently trading at $0.7 per share. It touched a 52-week high of $8.924 and a 52-week low of $8.924. Analysts tracking the stock have a 12-month average target price of $80.
Its 50-day moving average was $1.43 and 200-day moving average was $3.3 The short ratio stood at 3.58 indicating a short percent outstanding of 0%.
Around 154.1% of the company’s stock are held by insiders while 1965.7% are held by institutions.
Frequently Asked Questions About AcelRx Pharmaceuticals Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.